Molecular biology of prostate cancer

被引:44
作者
Schulz, WA [1 ]
Burchardt, M [1 ]
Cronauer, MV [1 ]
机构
[1] Univ Dusseldorf, Dept Urol, D-40225 Dusseldorf, Germany
关键词
androgens; epigenetics; expression profiling; oncogene; tumour suppressor;
D O I
10.1093/molehr/gag064
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
In spite of progress in diagnosis and treatment, prostate cancer has become one of the most frequent lethal cancers in males in many Western industrialized countries. Research on the molecular biology of prostate cancer is expected to reveal those aspects of Western lifestyle contributing to its high incidence with the aims of improving prevention, distinguishing slow-growing from aggressive clinically relevant cancers, and providing targets for treatment, particularly of locally advanced and of metastatic disease. Traditionally, prostate cancer research focused on androgens. More recently, tumour suppressors and proto-oncogenes important in other human cancers have been intensely investigated. Current approaches include the search for genes mutated in familial cases, identification of recurrent chromosomal alterations and their associated potential tumour suppressor genes, determination of gene expression profiles characterizing tumour stages and subclasses, and elucidation of the importance of epigenetic alterations. Results from such studies have begun to be translated into the clinic. Further successful transfer of results from molecular biology to the clinic will, however, require integration of the amassed molecular data into a biological framework model of prostate carcinoma.
引用
收藏
页码:437 / 448
页数:12
相关论文
共 158 条
[41]  
Gao AC, 1997, CANCER RES, V57, P846
[42]   APC/CTNNB1 (β-catenin) pathway alterations in human prostate cancers [J].
Gerstein, AV ;
Almeida, TA ;
Zhao, GJ ;
Chess, E ;
Shih, IM ;
Buhler, K ;
Pienta, K ;
Rubin, MA ;
Vessella, R ;
Papadopoulos, N .
GENES CHROMOSOMES & CANCER, 2002, 34 (01) :9-16
[43]   Chemotherapy for prostate cancer [J].
Gilligan, T ;
Kantoff, PW .
UROLOGY, 2002, 60 (3A) :94-100
[44]  
Giovannucci E, 1999, ADV EXP MED BIOL, V472, P29
[45]  
GLEASON DONALD F., 1966, CANCER CHEMO THERAP REP, V50, P125
[46]  
Goessl C, 2001, ANN NY ACAD SCI, V945, P51
[47]   Cancer prevention clinical trials [J].
Greenwald, P .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (18) :14S-22S
[48]  
Gregory CW, 2001, CANCER RES, V61, P4315
[49]  
Grimberg A, 2000, J CELL PHYSIOL, V183, P1, DOI 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO
[50]  
2-J